Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 12
Submit an article Journal homepage
267
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Clonal shifts in MDS – from SF3B1 to EZH2

André Barbosa RibeiroDepartment of Clinical Hematology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; ;Centre of Investigation in Environment, Genetics and Oncobiology – CIMAGO, Coimbra, Portugal; ;Laboratory of Oncobiology and Hematology, University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-5497-2310
ORCID Icon,
Margarida CouceloDepartment of Clinical Hematology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; ORCID Iconhttp://orcid.org/0000-0002-3426-6363
ORCID Icon,
Rita TenreiroDepartment of Clinical Hematology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal;
,
Ana Teresa SimõesDepartment of Clinical Hematology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal;
,
Gilberto MarquesDepartment of Clinical Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
,
Letícia RibeiroDepartment of Clinical Hematology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; ;Centre of Investigation in Environment, Genetics and Oncobiology – CIMAGO, Coimbra, Portugal; ORCID Iconhttp://orcid.org/0000-0002-5964-5001
ORCID Icon,
Emília CortesãoDepartment of Clinical Hematology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; ;Centre of Investigation in Environment, Genetics and Oncobiology – CIMAGO, Coimbra, Portugal; ;Laboratory of Oncobiology and Hematology, University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; ORCID Iconhttp://orcid.org/0000-0002-6655-1441
ORCID Icon &
Ana Bela Sarmento-RibeiroDepartment of Clinical Hematology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; ;Centre of Investigation in Environment, Genetics and Oncobiology – CIMAGO, Coimbra, Portugal; ;Laboratory of Oncobiology and Hematology, University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; ORCID Iconhttp://orcid.org/0000-0002-4142-4841
ORCID Icon show all
Pages 2994-2997 | Received 23 Oct 2017, Accepted 17 Feb 2018, Published online: 04 Apr 2018

References

  • Hasserjian R. MDS overview. WHO Classif. Tumours Haematop. Lymphoid Tissues, Revis. 4th Ed. Lyon: IARC Press; 2017.
  • Bejar R. Implications of molecular genetic diversity in myelodysplastic syndromes. Curr Opin Hematol. 2017;24:73–78.
  • Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17:5–19.
  • Malcovati L, Karimi M, Papaemmanuil E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126:233–241.
  • Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016;30:2214–2220.
  • Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–247.
  • da Silva-Coelho P, Kroeze LI, Yoshida K, et al. Clonal evolution in myelodysplastic syndromes. Nat Commun. 2017;8:15099.
  • Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2016;49:204–212.
  • Cortesão E, Tenreiro R, Ramos S, et al. Serum erythropoietin as prognostic marker in myelodysplastic syndromes. Acta Med Port. 2015;28:720–725.
  • Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev. 2009;23:S15–S19.
  • Delforge M, Selleslag D, Beguin Y, et al. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res. 2014;38:557–563.
  • Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–2506.
  • Cabrero M, Wei Y, Yang H, et al. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res. 2016; 44:1–7.
  • Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124: 1513–1521.
  • Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18:1338–1347.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.